Notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming to eliminate bacterial promoters of colorectal cancer through intraluminal application (RNX-051).

Pharma Equity Group's subsidiary has received notification from the European Patent Office regarding the decision to grant their patent for drug compositions aiming to eliminate bacterial promoters...

Related Keywords

United Kingdom ,Copenhagen ,Køavn ,Denmark , ,Company Announcement No ,Pharma Equity Group ,International Agency For Research On Cancer ,European Patent Office ,World Health Organization ,Reponex Pharmaceuticals ,Equity Group ,Thomas Kaas Sels ,International Agency ,Supplementary Protection Certificate ,Kaas Sels ,Nasdaq Copenhagen ,Reponex Pharmaceutical ,Markets ,